LUMO: Lumos Pharma, Inc. Company Short-Term Debt

Symbol and logo of brand Lumos Pharma, Inc. (LUMO)

Lumos Pharma, Inc. (LUMO) is developing a comprehensive approach to the therapy of pediatric endocrine pathologies, replacing growth hormone injections with convenient tablets. As the drugs undergo clinical trials, the current asset value is independent of market prices, and the indicator stands at 0.00. The share price illustrated below confirms the status of a company whose developments are protected by patents and exclusive FDA orphan drug designation.

LUMO (Lumos Pharma Inc) Company Short-Term Debts history from 07/04/2022 to 12/21/2024

LUMO (Lumos Therapeutics): analytical breakdowns and indicator data

- current quotes and average value forecast:
Price Chart Lumos Pharma|LUMO - Fair Value Consensus
- market capitalization information:
Market Value Lumos Pharma, Inc.|LUMO - Real Price to Acquire Entire Company
- shareholders' equity book value data:
Book Value per Share Lumos Pharma|LUMO - Book Capitalization|Market Cap to Net Assets Ratio lumos-pharma.com|LUMO - Aggregate Asset Value
- debt and liquidity data:
Debt to Equity Lumos Pharma, Inc.|LUMO - Long-Term Debt to Equity Ratio|Short-Term Debt to Capital Lumos Pharma, Inc.|LUMO - Company Cumulative Debt|Debt to Book Value Lumos Pharma, Inc.|LUMO - Amount of Long-Term Liabilities|Company Short-Term Debts Lumos Pharma|Quick Ratio lumos-pharma.com
- net income and valuation multiples indicators:
LUMO - Company Net Income
Basic company analysis:Lumos Pharma - LUMO
Mass-produced product of Lumos Therapeutics

For an investor in Lumos Pharma, Inc. (LUMO), which is leading the development of drugs for metabolic disorders without current sales, liquidity control is critical to maintaining patent protection. An analysis of short-term debt, which currently stands at 0.00, allows for the identification of hidden debt risks and an assessment of the company's ability to fund clinical trials without emergency capital raises, thereby determining the long-term sustainability of the business.

Who Lumos Pharma, Inc. competes with

ASND - Company Short-Term Debt|Company Short-Term Loans and Borrowings MDGL (Madrigal Pharmaceuticals Inc)|Corcept (CORT) - Company Short-Term Debt|Company Current Liabilities Rhythm Corp|AKRO (Akero Therapeutics) - Company Short-Term Debts|Company Short-Term Debts metsera.com|Company Current Liabilities MLTX (MoonLake)|CRNX (Crinetics Pharmaceuticals, Inc.) - Company Short-Term Loans and Borrowings|Company Short-Term Debt NewAmsterdam Pharma N.V. NAMS|SLNO - Company Current Liabilities|Amicus Therapeutics - Company Short-Term Debts|Short-Term Debt 89bio.com|AGIO (Agios Pharmaceuticals, Inc.) - Company Current Liabilities|GPCR: Amount of Current Liabilities|MDXG (MiMedx Group) - Company Short-Term Debts|Company Short-Term Debts Rezolute Bio|Company Short-Term Debts LXRX|Company Short-Term Debt MBX (mbxbio.com)|Company Short-Term Debt Altimmune ALT|Aardvark Therapeutics Inc. (AARD) - Short-Term Debt|SGMT - Company Short-Term Debt|BIOA: Company Short-Term Debt|BMEA: Company Short-Term Debts|QNCX - Short-Term Debt Volume|Company Short-Term Debt Fractyl Health|vTv Therapeutics Inc (VTVT) - Short-Term Debt Volume|Company Short-Term Debt Agape ATP Corporation (ATPC)|Company Current Liabilities pluri-biotech.com PLUR|Company Short-Term Debt Synlogic SYBX|lipocine.com - Company Short-Term Debt|MTNB: Company Current Liabilities|SPRB - Company Short-Term Debts|Galecto Corp (GLTO) - Company Short-Term Debt|Company Current Liabilities Carmell Therapeutics|Company Short-Term Debt Organovo Holdings, Inc.|Short-Term Debt radiuspharm.com RDUS